Clinical trials: Malignant Pain
Chronic Pain
An Efficacy and Safety Study of Transdermal Therapeutic System (TTS)-Fentanyl in Thai Participants With Chronic Non-Malignant Pain
The purpose of this study is to evaluate the efficacy and safety of Transdermal Therapeutic System (TTS)-fentanyl patch (transdermal patch containing a drug that is put on the skin so the drug will enter the body through the…
- Trial name
- NCT01816243
- Testing
- TTS-Fentanyl, Morphine
- Where
- 2 sites in Thailand
- Volunteers
- 39 people
- Sponsor
- Janssen-Cilag Ltd.,Thailand
Chronic Pain
Efficacy and Safety of Oxymorphone Extended Release in Opioid-Experienced Patients With Chronic Non-Malignant Pain
The purpose of this study is to evaluate the analgesic efficacy and safety of oxymorphone extended release in opioid-experienced patients with chronic low back pain.
- Trial name
- NCT00226421
- Testing
- Oxymorphone Extended Release
- Where
- 31 sites in United States
- Volunteers
- 120 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Non Cancer Pain
Targin for Non-cancer Pain
To determine the improvement in symptoms of constipation in subjects receiving treatment with oxycodone/naloxone prolonged release tablets (OXN) compared to oxycodone prolonged release tablets (OXY) based on the Bowel Function…
- Trial name
- NCT01918098
- Testing
- Oxycodone/naloxone prolonged release tablets
- Where
- 31 sites in China
- Volunteers
- 230 people
- Sponsor
- Mundipharma (China) Pharmaceutical Co. Ltd
Pain, Bone Neoplasm
A Study to Assess the Efficacy of Intravenous/Oral Bondronat (Ibandronate) in Patients With Metastatic Bone Disease Experiencing Moderate to Severe Pain
This 2 arm study will compare the efficacy of a regimen of intravenous (iv) and oral Bondronat with that of zoledronic acid in patients with malignant bone disease experiencing moderate to severe pain.
- Conditions
- Pain, Bone Neoplasm, Neoplasm Metastasis
- Trial name
- NCT00099177
- Testing
- ibandronate [Bondronat], zoledronic acid
- Where
- 41 sites in United States, Argentina and 14 more
- Volunteers
- 96 people
- Sponsor
- Hoffmann-La Roche
Pain; Bone Neoplasms; Neoplasm Metastasis
A Study of Ibandronate (Bondronat) in Participants With Malignant Bone Disease
This study will assess the efficacy and safety of ibandronate (Bondronat), administered intravenously (IV) or orally (PO), in participants with malignant bone disease and moderate to severe pain.
- Trial name
- NCT02561039
- Testing
- Ibandronate
- Where
- 9 sites in Bulgaria
- Volunteers
- 97 people
- Sponsor
- Hoffmann-La Roche
Pain, Osteoarthritis
An Open-label Extension Study With Flexible Dosing of Extended-release (ER) Tapentadol (CG5503) to Treat Patients With Moderate to Severe Chronic Pain
The purpose of the study is to assess the long-term safety profile of Tapentadol (CG5503) extended release (ER) at dosages ranging from 100 to 250 mg twice a day in treating patients with moderate to severe chronic pain over a…
- Conditions
- Pain, Osteoarthritis, Low Back Pain
- Trial name
- NCT00487435
- Testing
- Tapentadol (CG5503) Extended Release (ER)
- Where
- 148 sites in United States, Australia and 2 more
- Volunteers
- 1,166 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Chronic Pain
OXN PR Tablet 5/2.5 mg and20/10 mg PK Study in Chinese Moderate to Severe Chronic Non-malignant Patients
This is an open-label, randomized, single-dose, parallel group study. The objectives of this study are to assess pharmacokinetics of oxycodone and naloxone from oxycodone/naloxone (OXN) prolonged release (PR) tablet 5/2.5 mg (OXN…
- Trial name
- NCT02880475
- Testing
- OXN PR tablet
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Mundipharma (China) Pharmaceutical Co. Ltd
Chronic Non-Malignant Pain
Efficacy and Safety of Hydromorphone Hydrochloride Extended-Release Compared to Placebo in Subjects With Persistent Pain
The objective of this study is to assess the efficacy and safety of 8 mg Hydromorphone Hydrochloride Extended-Release.
- Trial name
- NCT00365898
- Testing
- Hydromorphone Hydrochloride Extended-Release
- Where
- 14 sites in United States
- Volunteers
- 380 people
- Sponsor
- Purdue Pharma LP
Pain
A Study of the Effectiveness and Safety of Sustained-release Hydromorphone (a Strong Opioid) in Patients With Chronic Noncancer Pain.
The purpose of this study is to compare the effectiveness and safety of sustained- release hydromorphone, formulated to release slowly over time, taken once daily, and controlled- release oxycodone taken twice daily, in patients…
- Trial name
- NCT00261495
- Testing
- OROS hydromorphone HCl, Oxycodone
- Where
- 52 sites in Czechia, Denmark and 8 more
- Volunteers
- 504 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Constipation
Study Evaluating Oral MOA-728 for the Treatment of Opioid-Induced Bowel Dysfunction (OIBD) in Subjects With Chronic Non-Malignant Pain
The primary purpose of the protocol is to evaluate the safety, efficacy, and tolerability of MOA-728 in subjects with Opioid-Induced Bowel Dysfunction (OIBD) with associated chronic non-malignant pain.
- Trial name
- NCT00366431
- Testing
- MOA-728
- Where
- 67 sites in United States
- Volunteers
- 420 people
- Sponsor
- Bausch Health Americas, Inc.
Pain, Analgesics
A Repeated-Dose Evaluation of a Pain Relieving Drug Use and Safety of OROS Hydromorphone HCI in Patients With Chronic Non-Malignant Pain
The purpose of this repeated dose study is to develop recommended dosing information for initiation of therapy with OROS Hydromorphone in patients with chronic non-malignant pain converting from other strong oral or transdermal…
- Conditions
- Pain, Analgesics, Opioid
- Trial name
- NCT00410644
- Testing
- OROS Hydromorphone HCI
- Volunteers
- 463 people
- Sponsor
- Alza Corporation, DE, USA
Pain, Constipation
A Study to Demonstrate Improvement in Symptoms of Constipation in Subjects That Require Around-the-clock Opioid Pain Killer Therapy
The primary research objective is to demonstrate that subjects taking OXN PR have improvement in symptoms of constipation as measured by the Bowel Function Index (BFI) compared to subjects taking OxyPR tablets alone with cancer…
- Trial name
- NCT01438567
- Testing
- oxycodone/naloxone prolonged release (OXN PR) tablets, oxycodone prolonged release (OxyPR) tablets
- Where
- United Kingdom
- Volunteers
- 270 people
- Sponsor
- Mundipharma Research GmbH & Co KG
Neoplasms
A Safety and Efficacy Study of Oral Tapentadol Extended-Release in Japanese Participants
The purpose of this study is to evaluate the conversion rate based on the number of participants achieving pain control and safety within 1 week after switching the opioid (morphine-like medications) analgesics (drug used to…
- Trial name
- NCT01309386
- Testing
- Tapentadol ER, Morphine SR
- Where
- 22 sites in Japan
- Volunteers
- 100 people
- Sponsor
- Janssen Pharmaceutical K.K.
Chronic Pain
An Interventional Study to Compare the Efficacy and Tolerability With Targin® in Non-malignant Chronic Pain (GLORY)
Objectives: 1. Objective of main interest To assess the drop-out rate caused by adverse event* after 6 weeks treatment 2. Further objectives To assess the drop-out rate caused by adverse event* after 1 week treatment To assess…
- Trial name
- NCT01811186
- Testing
- Oxycodone/naloxone
- Where
- South Korea
- Volunteers
- 261 people
- Sponsor
- Mundipharma Korea Ltd
Cancer, Chronic Pain
Tapentadol in Chronic Malignant Tumour Related Pain
The purpose of this trial is the characterization of the long term safety profile and long-term dose requirements of tapentadol PR (prolonged release) in patients with malignant tumor-related pain.
- Conditions
- Cancer, Chronic Pain, Pain
- Trial name
- NCT01264887
- Testing
- Tapentadol Prolonged Release
- Where
- 12 sites in Bulgaria, Hungary and 5 more
- Volunteers
- 31 people
- Sponsor
- Grünenthal GmbH
Tumor, Pain
A Study to Evaluate Tapentadol (CG5503) in the Treatment of Chronic Tumor-Related Pain Compared With Placebo and Morphine
The purpose of this study will be to determine whether tapentadol (CG5503) is effective and safe in the treatment of chronic tumor related pain compared to placebo.
- Trial name
- NCT00472303
- Testing
- Tapentadol Extended Release, Morphine Sulphate Controlled Release
- Where
- 71 sites in Austria, Bulgaria and 14 more
- Volunteers
- 622 people
- Sponsor
- Grünenthal GmbH
Pain
Safety, Pharmacokinetics (PK), and Effectiveness of Hydrocodone Bitartrate (HYD) Extended-Release Tablets in Children
The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and effectiveness of Hydrocodone Bitartrate (HYD) tablets in children with moderate to severe pain requiring around-the-clock opioid analgesics.
- Trial name
- NCT02542098
- Testing
- HYD tablets
- Sponsor
- Purdue Pharma LP
Chronic Nonmalignant Pain
Safety of Buprenorphine Transdermal Systems in Subjects With Chronic Nonmalignant Pain - a 28-week Extension Study
The objective of this study was to evaluate the long-term safety and tolerability of 7-day BTDS in a 28-week open-label extension phase in subjects with chronic nonmalignant pain syndromes whose pain had been previously…
- Trial name
- NCT01151098
- Testing
- Buprenorphine transdermal patch
- Where
- 19 sites in United States
- Volunteers
- 189 people
- Sponsor
- Purdue Pharma LP